弥漫性大B细胞淋巴瘤
医学
磁共振成像
淋巴瘤
代谢组学
肿瘤科
内科学
核医学
病理
核磁共振
癌症研究
生物信息学
放射科
生物
物理
作者
Martin Stenson,Anders Pedersen,Sverker Hasselblom,Herman Nilsson‐Ehle,Göran Karlsson,Rui Pinto,Per‐Ola Andersson
标识
DOI:10.3109/10428194.2016.1140164
摘要
The prognosis for diffuse large B-cell lymphoma (DLBCL) patients with early relapse or refractory disease is dismal. To determine if clinical outcome correlated to diverse serum metabolomic profiles, we used (1)H nuclear magnetic resonance (NMR) spectroscopy and compared two groups of DLBCL patients treated with immunochemotherapy: i) refractory/early relapse (REF/REL; n=27) and ii) long-term progression-free (CURED; n = 60). A supervised multivariate analysis showed a separation between the groups. Among discriminating metabolites higher in the REF/REL group were the amino acids lysine and arginine, the degradation product cadaverine and a compound in oxidative stress (2-hydroxybutyrate). In contrast, the amino acids aspartate, valine and ornithine, and a metabolite in the glutathione cycle, pyroglutamate, were higher in CURED patients. Together, our data indicate that NMR-based serum metabolomics can identify a signature for DLBCL patients with high-risk of failing immunochemotherapy, prompting for larger validating studies which could lead to more individualized treatment of this disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI